Target- |
MechanismImmunostimulants |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
单中心、开放性临床试验评价流感病毒裂解疫苗在3岁及以上人群接种的安全性I期临床试验
[Translation] A single-center, open-label clinical trial to evaluate the safety of influenza virus split vaccine in people aged 3 years and above Phase I clinical trial
评价流感病毒裂解疫苗在3岁及以上人群中接种1剂/2剂(3~8岁组)后的安全性。探索流感病毒裂解疫苗在3岁及以上人群中接种1剂/2剂(3~8岁组)后的免疫原性。
[Translation] To evaluate the safety of influenza virus split vaccine in people aged 3 years and above after 1 dose/2 doses (3-8 years old group). To explore the immunogenicity of influenza virus split vaccine in people aged 3 years and above after 1 dose/2 doses (3-8 years old group).
100 Clinical Results associated with Shanxi Peisen Biotechnology Co., Ltd.
0 Patents (Medical) associated with Shanxi Peisen Biotechnology Co., Ltd.
100 Deals associated with Shanxi Peisen Biotechnology Co., Ltd.
100 Translational Medicine associated with Shanxi Peisen Biotechnology Co., Ltd.